147 related articles for article (PubMed ID: 30129504)
1. Beta-cell Function and Metabolic Clearance Rate of Glucose in Patients with Major Mental Health Disorders on Antipsychotic Drug Treatment.
Akinlade KS; Rahamon SK; Lasebikan VO
J Natl Med Assoc; 2018 Oct; 110(5):504-511. PubMed ID: 30129504
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.
Cohen D; Stolk RP; Grobbee DE; Gispen-de Wied CC
Diabetes Care; 2006 Apr; 29(4):786-91. PubMed ID: 16567816
[TBL] [Abstract][Full Text] [Related]
4. Atypical antipsychotics and glucose homeostasis.
Bergman RN; Ader M
J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
[TBL] [Abstract][Full Text] [Related]
5. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients.
Haupt DW; Fahnestock PA; Flavin KA; Schweiger JA; Stevens A; Hessler MJ; Maeda J; Yingling M; Newcomer JW
Neuropsychopharmacology; 2007 Dec; 32(12):2561-9. PubMed ID: 17375138
[TBL] [Abstract][Full Text] [Related]
6. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.
Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC
Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome: differences between psychiatric and internal medicine patients.
Margari F; Lozupone M; Pisani R; Pastore A; Todarello O; Zagaria G; Minerva F; Palasciano G; Palmieri V
Int J Psychiatry Med; 2013; 45(3):203-26. PubMed ID: 24066405
[TBL] [Abstract][Full Text] [Related]
8. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.
Melkersson KI; Hulting AL; Brismar KE
J Clin Psychiatry; 1999 Nov; 60(11):783-91. PubMed ID: 10584769
[TBL] [Abstract][Full Text] [Related]
9. Association of Protein Kinase B (AKT) DNA Hypermethylation with Maintenance Atypical Antipsychotic Treatment in Patients with Bipolar Disorder.
Burghardt KJ; Seyoum B; Dass SE; Sanders E; Mallisho A; Yi Z
Pharmacotherapy; 2018 Apr; 38(4):428-435. PubMed ID: 29484683
[TBL] [Abstract][Full Text] [Related]
10. Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder.
Vincenzi B; Greene CM; Ulloa M; Parnarouskis L; Jackson JW; Henderson DC
J Psychiatr Pract; 2016 May; 22(3):175-82. PubMed ID: 27123797
[TBL] [Abstract][Full Text] [Related]
11. Psychotic and Bipolar Disorders: Antipsychotic Drugs.
Holder SD; Edmunds AL; Morgan S
FP Essent; 2017 Apr; 455():23-29. PubMed ID: 28437058
[TBL] [Abstract][Full Text] [Related]
12. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model.
Boyda HN; Tse L; Procyshyn RM; Wong D; Wu TK; Pang CC; Barr AM
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):945-54. PubMed ID: 20452386
[TBL] [Abstract][Full Text] [Related]
13. Quetiapine treatment in youth is associated with decreased insulin secretion.
Ngai YF; Sabatini P; Nguyen D; Davidson J; Chanoine JP; Devlin AM; Lynn FC; Panagiotopoulos C
J Clin Psychopharmacol; 2014 Jun; 34(3):359-64. PubMed ID: 24633003
[TBL] [Abstract][Full Text] [Related]
14. [Effect of atypical antipsychotics on metabolism].
Bakos CD; Berecz R; Degrell I
Neuropsychopharmacol Hung; 2004 Jun; 6(2):86-9. PubMed ID: 15787207
[TBL] [Abstract][Full Text] [Related]
15. Association of adipokines with metabolic disorders in patients with schizophrenia: Results of comparative study with mental healthy cohort.
Tanyanskiy DA; Martynikhin IA; Rotar OP; Konradi AO; Sokolian NA; Neznanov NG; Denisenko AD
Diabetes Metab Syndr; 2015; 9(3):163-7. PubMed ID: 25952038
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
17. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Chiu CC; Chen KP; Liu HC; Lu ML
J Clin Psychopharmacol; 2006 Oct; 26(5):504-7. PubMed ID: 16974193
[TBL] [Abstract][Full Text] [Related]
18. Metabolic studies of atypical antipsychotic agents and diabetes.
Postgrad Med; 2003 Dec; 114(6 Suppl Managing Metabolic):72-9. PubMed ID: 19667654
[TBL] [Abstract][Full Text] [Related]
19. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study.
Mackin P; Watkinson HM; Young AH
Diabetologia; 2005 Feb; 48(2):215-21. PubMed ID: 15688206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
